natgillin/translations-raw huggingface dataset:
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in Paget's disease of the bone, osteoporosis in post-menopausal women at an increased risk of fracture, osteoporosis in men at increased risk of fracture and prevention of clinical fractures after a hip fracture in men and women (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij referenčnega zdravila, ki vsebuje zoledronsko kislino za vse skupine pediatrične populacije s Pagetovo boleznijo kosti, za osteoporozo pri postmenopavzalnih ženskah s povečanim tveganjem za zlome, za osteoporozo pri moških s povečanim tveganjem za zlome in za preprečevanje kliničnih zlomov po zlomu kolka pri ženskah in moških (za podatke o uporabi pri pediatrični populaciji glejte poglavje
The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic acid Teva Generics.
Večina neželenih učinkov, kot so vročina z mrzlico, bolečine v mišicah in sklepih in glavobol, nastopi v prvih treh dneh po odmerku zdravila Zoledronska kislina
Zoledronic acid Teva Generics must not be mixed or given intravenously with any other medicinal product and must be given through a separate vented infusion line at a constant infusion rate.
Zdravila Zoledronska kislina Teva Generics ne smete mešati ali dajati intravensko z drugim zdravilom, dajati ga morate po ločenem prezračevanem infuzijskem sistemu s stalno hitrostjo infundiranja.
- Do not use this medicine if you notice any discolouration or particles in the solution.
- Ne uporabljajte tega zdravila, če opazite, da je raztopina drugačne barve ali so v njej majhni
If you feel dizzy while taking Zoledronic acid Teva Generics, do not drive or use machines until you feel better.
Če ste v obdobju zdravljenja z zdravilom Zoledronska kislina Teva Generics omotični, ne vozite in ne upravljajte strojev, dokler se vaše počutje ne izboljša.
Re-treatment of Paget's disease: After initial treatment with zoledronic acid in Paget's disease an extended remission period is observed in responding patients.
Ponovno zdravljenje Pagetove bolezni: Po začetnem zdravljenju Pagetove bolezni z zoledronsko kislino opažajo pri bolnikih, ki se odzovejo na zdravljenje, obdobje dolgotrajne remisije.
The study was not powered to show a reduction in clinical fractures compared to risedronate.
S študijo ni bilo mogoče pokazati manjše pogostnosti kliničnih zlomov v primerjavi z uporabo risedronata.
All cause mortality was 10% (101 patients) in the zoledronic acid-treated group compared to 13% (141 patients) in the placebo group.
Umrljivost iz kateregakoli vzroka je bila 10 % v skupini, zdravljeni z zoledronsko kislino (101 bolnik), v primerjavi s 13 % v skupini s placebom (141 bolnikov).
The early disposition phases (α and β, with t½ values above) presumably represent rapid uptake into bone and excretion via the kidneys.
Obe zgodnji obdobji prisotnosti zdravila v obtoku (α in β, z zgoraj navedenima vrednostima t½) sta po vsej verjetnosti obdobji hitrega privzema v kostnino in izločanja preko ledvic.
In the osteoporosis trials (PFT, HORIZON - Recurrent Fracture Trial [RFT]) the pooled atrial fibrillation incidences were comparable between zoledronic acid (2.6%) and placebo (2.1%).
V študijah osteoporoze (v PFT, v študiji HORIZON - študiji ponovnih zlomov (Recurrent Fracture Trial [RFT]) sta bili združeni incidenci atrijske fibrilacije primerljivi med zoledronsko kislino (2,6 %) in placebom (2,1 %).
• Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non smoking and healthy diet
• kontraindikacije med nosečnostjo in dojenjem, • potrebnost zadostnega nadomeščanja kalcija in vitamina D, ustrezne telesne dejavnosti in zdrave prehrane ter odsotnosti kajenja,
For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg zoledronic acid administered once a year.
Osteoporoza Za zdravljenje postmenopavzalne osteoporoze, osteoporoze pri moških in osteoporoze zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi je priporočeni odmerek ena intravenska infuzija s 5 mg zoledronske kisline enkrat na leto.
If you missed a dose of Zoledronic acid Teva Generics Contact your doctor or hospital as soon as possible to re-schedule your appointment.
Če ste izpustili odmerek zdravila Zoledronska kislina Teva Generics Čimprej pokličite zdravnika oziroma v bolnišnico, da se dogovorite za nov datum.
Zoledronic acid treatment rapidly reduced the rate of bone turnover from elevated post-menopausal levels with the nadir for resorption markers observed at 7 days, and for formation markers at 12 weeks.
Zdravljenje z zoledronsko kislino je hitro znižalo stopnjo pregradnje kosti z zvišanih postmenopavzalnih vrednosti; vrednosti označevalcev resorpcije so bile najnižje po 7 dneh, vrednosti označevalcev nastajanja kosti pa po 12 tednih.
During this entire time period bone turnover markers were within the pre-menopausal range at the end of each year.
V celotnem obdobju so bile ob koncu vsakega leta vrednosti označevalcev pregradnje kosti v okviru premenopavzalnih vrednosti.
Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Intravensko dana zoledronska kislina se odstranjuje iz telesa s trifaznim procesom: hitro dvofazno izginotje iz sistemskega krvnega obtoka z razpolovnima časoma t1/2α 0,24 ure in t1/2β 1,87 ure, ki mu sledi dolga faza izločanja s končnim razpolovnim časom izločanja t1/2χ 146 ur.
Patients were stratified with respect to duration of glucocorticoid use prior to randomisation (≤ 3 months versus > 3 months).
Bolnike so stratificiratli v dve podskupini glede na trajanje zdravljenja z glukokortikoidi pred randomizacijo (≤ 3 mesece oziroma > 3 mesece).
For information on the infusion of Zoledronic acid Teva Generics, see section 6.6.
Za informacije o infundiranju zdravila Zoledronska kislina Teva Generics glejte poglavje 6.6.
Other products containing zoledronic acid as active substances are available for oncology indications.
Obstajajo druga zdravila, ki vsebujejo zdravilno učinkovino zoledronska kislina in se uporabljajo za onkološke indikacije.
Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans.
Na podlagi teh rezultatov ni mogoče ugotavljati dejanskega vpliva zoledronske kisline na plodnost pri ljudeh.
It is currently unclear whether Zoledronic acid Teva Generics causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic acid Teva Generics.
Zaenkrat ni jasno, ali to nepravilno bitje srca povzroča zdravilo Zoledronska kislina Teva Generics, kljub temu pa morate zdravniku sporočiti, če pri vas pride do takih simptomov po prejemu zdravila Zoledronska kislina
The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Generics can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Generics administration
Incidenco simptomov po odmerjanju, ki nastopijo v prvih treh dneh po aplikaciji zdravila Zoledronska kislina Teva Generics, je mogoče znižati z jemanjem paracetamola ali ibuprofena kmalu po aplikaciji zdravila Zoledronska kislina Teva Generics.
Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely.
Redko se lahko pojavijo neobičajni zlomi stegnenice, še posebno pri bolnikih, ki so na dolgotrajnem zdravljenju osteoporoze.
Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men.
Osteoporoza je bolezen, pri kateri kosti postajajo bolj porozne in krhke, in je pogosta pri ženskah po menopavzi, vendar se lahko pojavi tudi pri moških.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy
Zdravljenje osteoporoze zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition.
Pri bolnikih, pri katerih se med difosfonatnim zdravljenjem razvije osteonekroza čeljusti, lahko stomatološka operacija poslabša stanje.
Zoledronic acid Teva Generics works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Zoledronska kislina Teva Generics deluje tako, da normalizira proces kostne pregradnje, omogoči tvorbo normalne kostnine in tako kostem povrne čvrstost.
No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects.
Starejši bolniki (≥ 65 let) Prilagajanje odmerjanja ni potrebno, ker so vrednosti biološke uporabnosti, porazdelitve in izločanja iz telesa pri starejših bolnikih in mlajših preiskovancih podobne.
Following the menopause bone loss occurs, bones become weaker and break more easily.
Zato po menopavzi pride do izgubljanja kostne mase, kosti postanejo bolj krhke in lomljive.
Before you receive dental treatment or undergo dental surgery, tell your dentist you are receiving treatment with Zoledronic acid Teva Generics.
Preden vam zobozdravnik začne zdraviti zobe ali opravi stomatološko operacijo, mu povejte, da prejemate zdravilo Zoledronska kislina Teva Generics.
Tabulated list of adverse reactions Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category.
Tabelaričen prikaz neželenih učinkov Neželeni učinki v preglednici 1 so navedeni glede na organski sitem po MedDRA klasifikaciji in glede na kategorijo pogostnosti.
In patients with Paget's disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Pri bolnikih s Pagetovo boleznijo so poročali o simptomih zaradi nizke koncentracije kalcija v krvi, kot so mišični krči, odrevenelost ali občutek zbadanja, posebno v predelu okrog ust.
Clinical efficacy in the treatment of post-menopausal osteoporosis (PFT) The efficacy and safety of zoledronic acid 5 mg once a year for 3 consecutive years were demonstrated in post-menopausal women (7,736 women aged 65-89 years) with either: a femoral neck bone mineral density (BMD) with a T-score ≤ -1.5 and at least two mild or one moderate existing vertebral fracture(s); or a femoral neck BMD T-score ≤ -2.5 with or without evidence of existing vertebral fracture(s).
Klinična učinkovitost pri zdravljenju postmenopavzalne osteoporoze (PFT) Učinkovitost in varnost zoledronske kisline 5 mg na leto 3 leta zapored so dokazali pri postmenopavzalnih ženskah (7.736 ženskah, starih 65-89 let), ki so imele: bodisi vrednost T mineralne gostote kosti vratu stegnenice ≤ -1,5, pri tem pa prisotna vsaj dva manjša zloma ali en srednje hud zlom vretenca, ali pa vrednost T mineralne gostote kosti vratu stegnenice ≤ -2,5 z znaki prisotnega enega ali več zlomov vretenc ali brez njih.
The usual dose is 5 mg, given to you as one initial infusion into a vein by your doctor or nurse.
Običajni odmerek je 5 mg in sicer vam ga da vaš zdravnik ali medicinska sestra v obliki začetne infuzije v veno.
Table 3 Between treatment comparisons of the incidence of key clinical fracture variables over 3 years
Preglednica 3 Primerjava incidenc ključnih kliničnih zlomov med obema načinoma zdravljenja v obdobju 3 let
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription.
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le s posebnim režimom.
In patients treated with zoledronic acid, no osteomalacia, marrow fibrosis or woven bone formation was detected.
Pri bolnicah, ki so se zdravile z zoledronsko kislino, niso odkrili osteomalacije, fibroze kostnega mozga ali tvorbe retikularne kostnine.
What Zoledronic acid Teva Generics is and what it is used for
Kaj je zdravilo Zoledronska kislina Teva Generics in za kaj ga uporabljamo
The overall percentage of patients who experienced adverse reactions were 44.7%, 16.7% and 10.2% after the first, second and third infusion, respectively.
Deleži vseh bolnikov, pri katerih je prišlo do neželenih učinkov, so bili po prvi infuziji 44,7 %, po drugi infuziji 16,7 %, po tretji infuziji pa 10,2 %.
• Monitoring of serum creatinine should be considered in at-risk patients.
• Pri bolnikih s povečanim tveganjem je treba razmisliti o spremljanju koncentracije kreatinina v
The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound's pharmacological antiresorptive activity.
Najpogostnejša ugotovitev v študijah s ponavljajočimi se odmerki je bila, da se je povečala primarna spongioza v metafizah dolgih kosti pri rastočih živalih pri skoraj vseh odmerkih.
Osteonecrosis of the jaw has multiple well documented risk factors including a diagnosis of cancer, concomitant therapies (e.g. chemotherapy, anti-angiogenic medicinal products, radiotherapy, corticosteroids) and co-morbid conditions (e.g. anaemia, coagulopathies, infection, pre-existing dental disease).
Osteonekroza čeljusti ima številne dobro dokumentirane dejavnike tveganja, ki vključujejo diagnozo raka, sočasno zdravljenje (npr. kemoterapijo, antiangiogena zdravila, radioterapijo, kortikosteroide) in sočasna bolezenska stanja (npr. anemijo,
The efficacy of one infusion of 5 mg zoledronic acid versus daily doses of 30 mg risedronate for 2 months was demonstrated in two 6-month comparative trials.
Ena infuzija 5 mg zoledronske kisline se je izkazala za bolj učinkovito kot odmerek 30 mg risedronata na dan v 2 mesecih v dveh 6-mesečnih primerjalnih preskusih.
In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with zoledronic acid and one patient treated with placebo.
V obsežnem kliničnem preskušanju s 7.736 bolniki so o osteonekrozi čeljusti poročali pri enem bolniku, ki je prejemal zoledronsko kislino,
Microcomputed tomography (μCT) analysis demonstrated increased trabecular bone volume and preservation of trabecular bone architecture in patients treated with zoledronic acid compared to placebo.
Analiza s pomočjo mikroračunalniške tomografije (μCT) je pokazala povečan volumen trabekularne kostnine in ohranjeno trabekularno strukturo kosti pri bolnicah, ki so se zdravile z zoledronsko kislino, v primerjavi s tistimi, ki so prejemale placebo.
The risk reduction was 51% in bisphosphonate-naïve patients and 42% in patients allowed to take concomitant osteoporosis therapy.
Zmanjšanje tveganja je bilo 51-odstotno v skupini bolnikov, ki še niso jemali difosfonatov, in 42-odstotno pri bolnikih, ki so lahko sočasno jemali druga zdravila za zdravljenje osteoporoze.
The safety and efficacy of zoledronic acid in children and adolescents below 18 years of age have not been established.
Pediatrična populacija Varnost in učinkovitost zoledronske kisline pri otrocih in mladostnikih starih do 18 let nista bili dokazani.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Teva B.V.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Teva B.V.
In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to zoledronic acid administration (see section 4.2).
V preskušanju preventive kliničnih zlomov po nedavnem zlomu kolka niso rutinsko merili koncentracij vitamina D, vendar je večina bolnikov pred aplikacijo zoledronske kisline prejela večji začetni odmerek vitamina D (glejte poglavje 4.2).
Identified in post-marketing experience.
† ugotovljeno z izkušnjami v obdobju po prihodu zdravila na trg.
Six patients who achieved therapeutic response 6 months after treatment with zoledronic acid and later experienced disease relapse during the extended follow-up period were re-treated with zoledronic acid after a mean time of 6.5 years from initial treatment to re-treatment.
Šest bolnikov, pri katerih je prišlo do terapevtskega odziva 6 mesecev po zdravljenju z zoledronsko kislino, kasneje v obdobju podaljšanega spremljanja pa do recidiva bolezni, je ponovno prejelo zoledronsko kislino, pri čemer je interval med začetnim in ponovnim zdravljenjem v povprečju znašal
What Zoledronic acid Teva Generics is and what it is used for What you need to know before you are given Zoledronic acid Teva Generics How Zoledronic acid Teva Generics is given Possible side effects
Kaj je zdravilo Zoledronska kislina Teva Generics in za kaj ga uporabljamo Kaj morate vedeti, preden vam dajo zdravilo Zoledronska kislina Teva Generics Kako se daje zdravilo Zoledronska kislina Teva Generics
Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone.
Mehanizem delovanja Zoledronska kislina spada v skupino difosfonatov, ki vsebujejo dušik, in deluje primarno na kost.
Any clinical fracture (1)
katerikoli klinični zlom (1) klinični zlom vretenca (2) nevretenčni zlom (1)
- if you are allergic to zoledronic acid, other bisphosphonates or any of the other ingredients of this medicine (listed in section 6).
- če ste alergični na zoledronsko kislino, druge difosfonate ali katero koli sestavino tega zdravila
Patients were randomised to either zoledronic acid 5 mg single infusion or to oral risedronate 5 mg daily for one year.
Bolnike so randomizirali tako, da so prejemali bodisi zoledronsko kislino v enkratni infuziji 5 mg ali risedronat v odmerku 5 mg enkrat na dan peroralno eno leto.
- The other ingredients are mannitol, sodium citrate and water for injections.
Druge pomožne snovi so: manitol, natrijev citrat in voda za injekcije.
Flu, upper respiratory tract infections, decreased red cell count, loss of appetite, sleeplessness, sleepiness which may include reduced alertness and awareness, tingling sensation or numbness, extreme tiredness, trembling, temporary loss of consciousness, eye infection or irritation or inflammation with pain and redness, spinning sensation, increased blood pressure, flushing, cough, shortness of breath, upset stomach, abdominal pain, constipation, dry mouth, heartburn, skin rash, excessive sweating, itching, skin reddening, neck pain, stiffness in muscles, bones and/or joints, joint swelling, muscle spasms, shoulder pain, pain in your chest muscles and rib cage, joint inflammation, muscular weakness, abnormal kidney test results, abnormal frequent urination, swelling of hands, ankles or feet, thirst, toothache, taste disturbances.
Gripa, okužbe zgornjih dihal, znižano število eritrocitov, izguba apetita, nespečnost, zaspanost, ki lahko vključuje upad pozornosti in zavesti, občutek mravljinčenja ali otrplosti, izjemna utrujenost, tresenje, začasna izguba zavesti, okužba ali draženje ali vnetje očesa z bolečino in rdečino, vrtoglavica, zvišan krvni tlak, navali rdečice, kašelj, zadihanost, razdražen želodec, bolečine v trebuhu, zapeka, suha usta, zgaga, izpuščaj, čezmerno znojenje, srbenje, rdečina kože, bolečine v vratu, okorelost mišic, kosti in/ali sklepov, otekanje sklepov, mišični krči, bolečine v rami, bolečine v mišicah prsnega koša in v rebrih, vnetje sklepov, šibkost mišic, nenormalni izvidi preiskav ledvic, nenormalno pogosto uriniranje, otekanje rok, gležnjev ali stopal, žeja, zobobol, motnje okušanja.
During post-marketing experience the following reactions have been reported (frequency rare): Atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction).
V obdobju trženja so poročali po naslednjih neželenih reakcijah (redki): atipični subtrohanterni zlomi stegnenice in zlomi diafize stegnenice (za difosfonate značilen neželeni učinek).
In the event of overdose leading to clinically significant hypocalcaemia, reversal may be achieved with supplemental oral calcium and/or an intravenous infusion of calcium gluconate.
Klinično pomembno hipokalciemijo, ki je posledica prevelikega odmerka, lahko odpravimo z dodatkom peroralnega kalcija ali intravensko infuzijo kalcijevega glukonata ali z obema.
Re-treatment consists of an additional intravenous infusion of 5 mg zoledronic acid after an interval of one year or longer from initial treatment in patients who have relapsed.
Ponovno zdravljene Pagetove bolezni kosti pomeni dodatno intravensko infuzijo zolendronske kisline 5 mg eno leto ali več po začetnem zdravljenju bolnikov, pri katerih pride do ponovitve bolezni.
You must not be given Zoledronic acid Teva Generics:
Zdravila Zoledronska kislina Teva Generics ne smete dobiti:
The pack sizes of 5 and 10 bottles are only available in multipacks.
Pakiranji po 5 in 10 plastenk sta na voljo v skupnem pakiranju.
It is an inhibitor of osteoclast-mediated bone resorption.
Je zaviralec resorpcije kosti, ki jo povzročajo osteoklasti.
Patients being treated with Zoledronic acid Teva Generics should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina Teva Generics, ne smejo istočasno prejemati teh zdravil ali kateri koli druge difosfonate, saj skupni učinki teh zdravil niso znani.
The clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.
Lečeči zdravnik naj se pri vodenju zdravljenja posameznega bolnika opira na klinično presojo na podlagi ocene individualnega razmerja med koristjo in tveganjem.
How to store Zoledronic acid Teva Generics Contents of the pack and other information
Shranjevanje zdravila Zoledronska kislina Teva Generics Vsebina pakiranja in dodatne informacije
Zoledronic acid significantly reduced the mean days of limited activity and the days of bed rest due to back pain by 17.9 days and 11.3 days respectively compared to placebo and significantly reduced the mean days of limited activity and the days of bed rest due to fractures by 2.9 days and 0.5 days respectively compared to placebo (all p<0.01).
Zoledronska kislina je v primerjavi s placebom statistično značilno znižala povprečno število dni z omejeno aktivnostjo za 17,9 dni v primerjavi s placebom in statistično značilno znižala povprečno število dni z omejeno aktivnostjo za 2,9 dni in število dni, v katerih je zaradi zlomov potreben počitek v postelji, za 0,5 dni (v vseh primerih p<0,01).
Uncommonly, cases of osteonecrosis (primarily of the jaw) have been reported, predominantly in cancer patients treated with bisphosphonates, including zoledronic acid.
O osteonekrozi (večinoma čeljusti) so občasno poročali predvsem pri bolnikih z rakom, zdravljenih z difosfonati, vključno z zoledronsko kislino.
- The unopened bottle does not require any special storage conditions.
- Neodprta plastenka: Za shranjevanje zdravila niso potrebna posebna navodila.
The rate of atrial fibrillation serious adverse events was increased in patients receiving zoledronic acid (1.3%) (51 out of 3,862) compared with patients receiving placebo (0.6%) (22 out of 3,852).
Delež atrijske fibrilacije, ki so jo opredelili kot resen neželen dogodek, je bil pri bolnikih, ki so prejemali zoledronsko kislino, višji (1,3 %) (pri 51 od 3.862 bolnikov) v primerjavi z bolniki, ki so prejemali placebo (0,6 %) (pri 22 od 3.852 bolnikov).
In patients with a recent low-trauma hip fracture, it is recommended to give the zoledronic acid infusion at least two weeks after hip fracture repair (see section 5.1).
Pri bolnikih z nedavnim zlomom kolka po lažji poškodbi je pripročeno dati infuzijo zoledronske kisline najmanj dva tedna po oskrbi zloma kolka (glejte poglavje 5.1).